Zobrazeno 1 - 10
of 732
pro vyhledávání: '"Carlile, D"'
Autor:
Djebli N; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland.; Luzsana Biotechnology, Clinical Pharmacology and Early Development, Basel, Switzerland., Parrott N; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland., Jaminion F; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland., O'Jeanson A; Department of Pharmacy, Uppsala University, Uppsala, Sweden., Guerini E; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland., Carlile D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Welwyn, UK.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 396-409. Date of Electronic Publication: 2023 Dec 14.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Worboys, P. D., Carlile, D. J.
Publikováno v:
Xenobiotica. Aug/Sept2001, Vol. 31 Issue 8/9, p539-556. 18p. 1 Chart, 5 Graphs.
Autor:
Patel, Y. T., Daryani, V. M., Patel, P., Zhou, D., Fangusaro, J., Carlile, D. J., Martin, P. D., Aarons, L., Stewart, C. F.
Publikováno v:
Patel, Y T, Daryani, V M, Patel, P, Zhou, D, Fangusaro, J, Carlile, D J, Martin, P D, Aarons, L & Stewart, C F 2017, ' Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas ', CPT: Pharmacometrics and Systems Pharmacology . https://doi.org/10.1002/psp4.12175
Selumetinib (AZD6244, ARRY-142886), a mitogen activated protein kinases (MEK1 and 2) inhibitor, has been granted orphan drug designation for differentiated thyroid cancer. The primary aim of this analysis was to characterize the population pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3818::6f86f595cb3a4f93aca81cfc4106890c
https://research.manchester.ac.uk/en/publications/830df0bb-ecd4-45cb-9598-1d83ddcf1bd9
https://research.manchester.ac.uk/en/publications/830df0bb-ecd4-45cb-9598-1d83ddcf1bd9
Autor:
Rawden, H. C.1, Carlile, D. J.2, Tindall, A.1, Hallifax, D.1, Galetin, A.1, Ito, K.3, Houston, J. B.1 Brian.Houston@manchester.ac.uk
Publikováno v:
Xenobiotica. Jun2005, Vol. 35 Issue 6, p603-625. 23p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Carlo‐Stella, C, Hutchings, M, Offner, F. C, Morschhauser, F, Bachy, E, Crump, M, Sureda, A, Iacoboni, G, Haioun, C, Perez‐Callejo, D, Lundberg, L, Relf, J, Clark, E, Carlile, D, Piccione, E, Belousov, A, Humphrey, K, Dickinson, M. J
Publikováno v:
Hematological Oncology; Jun2021 Supplement S2, Vol. 39, p1-3, 3p
Autor:
Edwards, Jena E.1,2 (AUTHOR) jena.edwards@nioz.nl, Buijse, Anthonie D.2,3 (AUTHOR), Winter, Hendrik V.2,4 (AUTHOR), Bijleveld, Allert I.1 (AUTHOR)
Publikováno v:
Animal Biotelemetry. 7/20/2024, Vol. 12 Issue 1, p1-18. 18p.
Autor:
Muschong, Patricia1 (AUTHOR) patricia.muschong@abbvie.com, Awwad, Khader1 (AUTHOR) khader.awwad@abbvie.com, Price, Edward2 (AUTHOR) edward.price@abbvie.com, Mezler, Mario1 (AUTHOR) mario.mezler@abbvie.com, Weinheimer, Manuel1 (AUTHOR) manuel.weinheimer@abbvie.com
Publikováno v:
Pharmaceutics. Jul2024, Vol. 16 Issue 7, p846. 20p.
Autor:
Zhang, Xinyuan1 (AUTHOR) xinzhang@dsi.com, Zhao, Ping2 (AUTHOR)
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. Jul2024, Vol. 13 Issue 7, p1083-1087. 5p.